Table 2. Clinicopathologic characteristics according to the AR and HER-2 status in ER-negative breast cancer.
| AR-positive group, n = 127 | AR-negative group, n = 207 | |||||||||
| Parameters | Sub-category | TotalN = 334 (%) | HER-2−n = 53 (%) | HER-2+n = 74 (%) | P-value | HER-2+n = 66 (%) | HER-2−n = 141 (%) | P-value | P-value* | P-value† |
| Age (years) | 0.936 | 0.030 | 0.001 | 0.003 | ||||||
| ≤35 | 34 (10.2) | 2 (3.8) | 3 (4.1) | 4 (6.1) | 25 (17.7) | |||||
| >35 | 300 (89.8) | 51 (96.2) | 71 (95.6) | 62 (93.9) | 116 (82.3) | |||||
| Histologic grade | 0.729 | 0.074 | 0.078 | 0.067 | ||||||
| I/II | 136 (40.7) | 26 (49.1) | 34 (45.9) | 30 (45.5) | 46 (32.6) | |||||
| III | 198 (59.3) | 27 (50.9) | 40 (54.1) | 36 (54.5) | 95 (67.4) | |||||
| T stage | 0.619 | 0.089 | 0.126 | 0.115 | ||||||
| T1 | 160 (47.9) | 27 (50.9) | 41 (55.4) | 35 (53.0) | 57 (40.4) | |||||
| T2/T3 | 174 (52.1) | 26 (49.1) | 33 (44.6) | 31 (47.0) | 84 (59.6) | |||||
| Lymph node metastasis | 0.839 | 0.354 | 0.594 | 0.373 | ||||||
| No | 245 (73.4) | 40 (75.5) | 57 (77.0) | 50 (75.8) | 98 (69.5) | |||||
| Yes | 89 (26.6) | 13 (24.5) | 17 (23.0) | 16 (24.2) | 43 (30.5) | |||||
| Tumor recurrence | 0.801 | 0.562 | 0.843 | 0.600 | ||||||
| No | 295 (88.3) | 48 (90.6) | 66 (89.2) | 59 (89.4) | 122 (86.5) | |||||
| Yes | 39 (11.7) | 5 (9.4) | 8 (10.8) | 7 (10.6) | 19 (13.5) | |||||
| Patient death | 0.950 | 0.442 | 0.242 | 0.080 | ||||||
| No | 303 (90.7) | 50 (94.3) | 70 (94.6) | 60 (90.9) | 123 (87.2) | |||||
| Yes | 31 (9.3) | 3 (5.7) | 4 (5.4) | 6 (9.1) | 18 (12.8) | |||||
| Ki-67 LI (%) | 0.294 | 0.002 | <0.001 | <0.001 | ||||||
| ≤14 | 79 (23.7) | 22 (41.5) | 24 (32.4) | 18 (27.3) | 15 (10.6) | |||||
| >14 | 31 (58.5) | 31 (58.5) | 50 (67.6) | 48 (72.7) | 126 (89.4) | |||||
*P-value was from comparison among 4 groups.
†
P-value was from comparison between AR+ and AR– groups by Fisher exact test.